Ticker: WINT

Quick take - Windtree Therapeutics, Inc. (NASDAQ: WINT) What's going on inside: management shifted strategy in January 2025 from pure R&D to becoming a parent company that acquires small, revenue-generating businesses and FDA‑approved products. Concurrently the company executed a series of financ...

Windtree Therapeutics Inc. (NASDAQ: WINT) has recently submitted its quarterly report for the period ending March 31, 2025. Here's a concise overview of the company's financial status and upcoming activities. Positive Aspects: Revenue Growth Potential: The company’s lead candidate, istaroxime, s...